<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232271</url>
  </required_header>
  <id_info>
    <org_study_id>2004-157</org_study_id>
    <nct_id>NCT00232271</nct_id>
  </id_info>
  <brief_title>The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.</brief_title>
  <official_title>The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart Foundation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Melbourne Health</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of the anticoagulant(blood thinner) Clexane
      on the development of leg clots following electrophysiology studies (EPS) and or
      radiofrequency ablation (RFA).

      People who suffer heart palpitations will sometimes need hospital admission to undergo an
      electrophysiology study ( and or a Radiofrequency Ablation)in order to diagnose and or treat
      their condition.

      Radiofrequency ablation is a procedure to stop abnormal heart rhythms. EPS/RFA studies
      require the puncture of the leg veins . Previous experience has shown that following the
      puncture of leg veins there is a small risk of developing a blood clot in the leg.

      It is not known whether giving blood thinners (anticoagulants) after the procedure will
      decrease this risk Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and
      safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the
      legs
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of deep vein thrombosis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>clexane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received clexane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non clexane</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no clexane given</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clexane</intervention_name>
    <arm_group_label>clexane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing EPS/RFA for the diagnosis and or treatment of SVT based on patient
             history or ECG evidence.

        Exclusion Criteria:

          -  Patients with a past history of DVT or PE.

          -  Patients with a history of clotting disorders

          -  Patients with active malignancies

          -  Patients requiring full heparinisation during and after the procedure.

          -  Chronic atrial flutter and atrial fibrillation ablation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sparks, MBBS, PhD. FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Melbourne hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2005</study_first_submitted>
  <study_first_submitted_qc>October 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

